Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer

Yuchuan Wang, Jen Chieh Tseng, Yanping Sun, Andrew H. Beck, Andrew L. Kung

Research output: Contribution to journalArticle

Abstract

Imaging plays a central role in the diagnosis of cancer and the evaluation of therapeutic efficacy in patients with cancer. Because macroscopic imaging is noninvasive and quantitative, the development of specialized instruments for small animals has spurred increasing utilization in preclinical cancer studies. Some small-animal imaging devices are miniaturized derivatives of clinical imaging modalities, including computed tomography, magnetic resonance imaging, positron-emission tomography, single-photon emission computed tomography, and ultrasonography. Optical imaging, including bioluminescence imaging and fluorescence imaging, has evolved from microscopic cellular imaging technologies. Here, we review how current imaging modalities are enabling high-resolution structural imaging with micrometer-scale spatial resolution, thus allowing for the quantification of tumor burden in genetically engineered and orthotopic models of cancer, where tumors develop within organs not typically accessible to measurements with calipers. Beyond measuring tumor size, imaging is increasingly being used to assess the activity of molecular pathways within tumors and to reveal the pharmacodynamic efficacy of targeted therapies. Each imaging technology has particular strengths and limitations, and we discuss how studies should be carefully designed to match the imaging approach to the primary experimental question.

Original languageEnglish (US)
Pages (from-to)135-144
Number of pages10
JournalCold Spring Harbor Protocols
Volume2015
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Tumor Burden
Tumors
Imaging techniques
Neoplasms
Optical Imaging
Technology
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Animals
Ultrasonography
Pharmacodynamics
Single photon emission computed tomography
Tomography
Bioluminescence
Magnetic Resonance Imaging
Positron emission tomography
Equipment and Supplies
Medical imaging
Magnetic resonance
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. / Wang, Yuchuan; Tseng, Jen Chieh; Sun, Yanping; Beck, Andrew H.; Kung, Andrew L.

In: Cold Spring Harbor Protocols, Vol. 2015, No. 2, 2015, p. 135-144.

Research output: Contribution to journalArticle

Wang, Yuchuan ; Tseng, Jen Chieh ; Sun, Yanping ; Beck, Andrew H. ; Kung, Andrew L. / Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. In: Cold Spring Harbor Protocols. 2015 ; Vol. 2015, No. 2. pp. 135-144.
@article{d010d7403e1d4f39872a69be358de7a3,
title = "Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer",
abstract = "Imaging plays a central role in the diagnosis of cancer and the evaluation of therapeutic efficacy in patients with cancer. Because macroscopic imaging is noninvasive and quantitative, the development of specialized instruments for small animals has spurred increasing utilization in preclinical cancer studies. Some small-animal imaging devices are miniaturized derivatives of clinical imaging modalities, including computed tomography, magnetic resonance imaging, positron-emission tomography, single-photon emission computed tomography, and ultrasonography. Optical imaging, including bioluminescence imaging and fluorescence imaging, has evolved from microscopic cellular imaging technologies. Here, we review how current imaging modalities are enabling high-resolution structural imaging with micrometer-scale spatial resolution, thus allowing for the quantification of tumor burden in genetically engineered and orthotopic models of cancer, where tumors develop within organs not typically accessible to measurements with calipers. Beyond measuring tumor size, imaging is increasingly being used to assess the activity of molecular pathways within tumors and to reveal the pharmacodynamic efficacy of targeted therapies. Each imaging technology has particular strengths and limitations, and we discuss how studies should be carefully designed to match the imaging approach to the primary experimental question.",
author = "Yuchuan Wang and Tseng, {Jen Chieh} and Yanping Sun and Beck, {Andrew H.} and Kung, {Andrew L.}",
year = "2015",
doi = "10.1101/pdb.top069930",
language = "English (US)",
volume = "2015",
pages = "135--144",
journal = "Cold Spring Harbor Protocols",
issn = "1559-6095",
publisher = "Cold Spring Harbor Laboratory Press",
number = "2",

}

TY - JOUR

T1 - Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer

AU - Wang, Yuchuan

AU - Tseng, Jen Chieh

AU - Sun, Yanping

AU - Beck, Andrew H.

AU - Kung, Andrew L.

PY - 2015

Y1 - 2015

N2 - Imaging plays a central role in the diagnosis of cancer and the evaluation of therapeutic efficacy in patients with cancer. Because macroscopic imaging is noninvasive and quantitative, the development of specialized instruments for small animals has spurred increasing utilization in preclinical cancer studies. Some small-animal imaging devices are miniaturized derivatives of clinical imaging modalities, including computed tomography, magnetic resonance imaging, positron-emission tomography, single-photon emission computed tomography, and ultrasonography. Optical imaging, including bioluminescence imaging and fluorescence imaging, has evolved from microscopic cellular imaging technologies. Here, we review how current imaging modalities are enabling high-resolution structural imaging with micrometer-scale spatial resolution, thus allowing for the quantification of tumor burden in genetically engineered and orthotopic models of cancer, where tumors develop within organs not typically accessible to measurements with calipers. Beyond measuring tumor size, imaging is increasingly being used to assess the activity of molecular pathways within tumors and to reveal the pharmacodynamic efficacy of targeted therapies. Each imaging technology has particular strengths and limitations, and we discuss how studies should be carefully designed to match the imaging approach to the primary experimental question.

AB - Imaging plays a central role in the diagnosis of cancer and the evaluation of therapeutic efficacy in patients with cancer. Because macroscopic imaging is noninvasive and quantitative, the development of specialized instruments for small animals has spurred increasing utilization in preclinical cancer studies. Some small-animal imaging devices are miniaturized derivatives of clinical imaging modalities, including computed tomography, magnetic resonance imaging, positron-emission tomography, single-photon emission computed tomography, and ultrasonography. Optical imaging, including bioluminescence imaging and fluorescence imaging, has evolved from microscopic cellular imaging technologies. Here, we review how current imaging modalities are enabling high-resolution structural imaging with micrometer-scale spatial resolution, thus allowing for the quantification of tumor burden in genetically engineered and orthotopic models of cancer, where tumors develop within organs not typically accessible to measurements with calipers. Beyond measuring tumor size, imaging is increasingly being used to assess the activity of molecular pathways within tumors and to reveal the pharmacodynamic efficacy of targeted therapies. Each imaging technology has particular strengths and limitations, and we discuss how studies should be carefully designed to match the imaging approach to the primary experimental question.

UR - http://www.scopus.com/inward/record.url?scp=84923788037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923788037&partnerID=8YFLogxK

U2 - 10.1101/pdb.top069930

DO - 10.1101/pdb.top069930

M3 - Article

C2 - 25646505

AN - SCOPUS:84923788037

VL - 2015

SP - 135

EP - 144

JO - Cold Spring Harbor Protocols

JF - Cold Spring Harbor Protocols

SN - 1559-6095

IS - 2

ER -